National Bank of Canada FI Buys 114,834 Shares of Illumina, Inc. (NASDAQ:ILMN)

National Bank of Canada FI raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 43.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 378,247 shares of the life sciences company’s stock after acquiring an additional 114,834 shares during the quarter. National Bank of Canada FI’s holdings in Illumina were worth $52,050,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Illumina during the 3rd quarter worth $30,000. VisionPoint Advisory Group LLC raised its stake in Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Illumina in the fourth quarter valued at about $37,000. Gradient Investments LLC increased its holdings in shares of Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares during the period. Finally, North Star Investment Management Corp. increased its holdings in shares of Illumina by 183.0% in the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 194 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 0.2 %

ILMN traded down $0.25 during trading on Monday, reaching $117.68. The company’s stock had a trading volume of 888,024 shares, compared to its average volume of 1,702,479. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91. The company’s fifty day moving average price is $130.03 and its 200-day moving average price is $127.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the company earned $0.08 EPS. The company’s quarterly revenue was down 1.0% on a year-over-year basis. Research analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of several research analyst reports. OTR Global reissued a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. Barclays increased their price target on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, StockNews.com lowered Illumina from a “buy” rating to a “hold” rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $165.10.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.